Dalmane 30 mg: Why This Long-Acting Sleeping Pill Demands Extra Caution

 Dalmane is a brand of flurazepam, a benzodiazepine that was once a standard treatment for insomnia. In the UK and Denmark, it has largely fallen out of routine use, and the brand itself is discontinued in several markets. But flurazepam still appears in clinical discussions, online pharmacies, and questions from patients who have been prescribed it or are considering it.

The reason it deserves a closer look is its half-life. Flurazepam is not a short-acting sleeping tablet that wears off by morning. Its active metabolite lingers in the body for days, and that changes everything about how it should be used—or whether it should be used at all.

The Active Ingredient and Its Long Tail

Dalmane 30 mg contains flurazepam hydrochloride, a sedative-hypnotic indicated for insomnia—specifically difficulty falling asleep and staying asleep . It works like other benzodiazepines, enhancing the effect of GABA, the brain's main inhibitory neurotransmitter.

What sets flurazepam apart is its metabolism. The parent drug is detectable in plasma for only about three hours after a dose. But one of its metabolites, desalkylflurazepam, reaches peak concentrations around ten hours after ingestion and then declines very slowly, with a mean half-life of roughly 71 hours in one study of healthy volunteers . Other research found the half-life ranged from 37 to 289 hours, and was significantly longer in elderly men than in young men .

That means a single 30 mg dose at bedtime can still be producing measurable effects days later. For a sleeping pill, that is an unusually long commitment.

Why This Matters More for Older Adults

The accumulation problem is not theoretical. A double-blind study of geriatric insomniacs compared temazepam and flurazepam and noted that the elderly are especially sensitive to the adverse effects of flurazepam's long-acting metabolite . The comparison was stark: temazepam's mean half-life was about ten hours, while flurazepam's active metabolite had a half-life of 65.5 hours .

In practice, this means a 75-year-old taking Dalmane 30 mg nightly is not clearing the drug between doses. It builds up. The consequences are the familiar benzodiazepine hazards amplified: next-day drowsiness, unsteadiness, confusion, and falls.

The FDA label for Dalmane lists dizziness, drowsiness, light-headedness, staggering, loss of coordination and falling as reported effects, "particularly in elderly or debilitated persons" . Severe sedation, lethargy, disorientation and coma have also been reported, probably indicative of intolerance or overdosage .

Side Effects Beyond Sedation

The FDA label catalogues a broader set of adverse reactions: headache, heartburn, upset stomach, nausea, vomiting, diarrhoea, constipation, nervousness, anxiety, irritability, weakness, pounding heartbeat, chest pain, body and joint pains, and difficulty urinating .

Liver injury is rare but documented. A case report describes a 44-year-old woman who developed cholestatic hepatitis after six months of intermittent flurazepam use, with jaundice and itching; her liver tests improved rapidly once the drug was stopped . The LiverTox database notes that benzodiazepine-related liver injury is uncommon and typically self-limited, but it is a recognised possibility .

There is also a practical interaction warning that matters for anyone with HIV or taking certain antiviral regimens. European product information for ritonavir states that co-administration with flurazepam is expected to increase flurazepam plasma concentrations and is therefore contraindicated .

Dalmane vs Restoril: A Question of Duration

Comparing Dalmane with Restoril (temazepam) is instructive because both are benzodiazepine hypnotics, but they behave very differently. Temazepam has a half-life in the range of 6 to 16 hours, while flurazepam's active metabolite sits at 47 to 100 hours in one clinical table . Temazepam is cleared relatively quickly; flurazepam is not.

That difference shapes prescribing. Temazepam is generally favoured for older patients precisely because it is less likely to accumulate. Flurazepam's long duration may suit someone with severe difficulty staying asleep, but it makes the drug a poor choice for anyone who needs to be alert the next day or who has any risk factors for falls.

Real-world data from eHealthMe, which aggregates patient-reported outcomes, shows flurazepam users reporting "drug ineffective" and "drug abuse" among the most common side effects, alongside anxiety and confusional state . This is not rigorous clinical trial data, but it reflects the messy reality of how long-acting sedatives perform outside controlled settings.

What Adults in the UK and Denmark Should Know

Dalmane is not a standard NHS or Danish formulary item. The brand has been discontinued in some markets, and flurazepam is not commonly prescribed in either country today . If you have obtained it online or from an overseas pharmacy, the lack of local regulatory oversight is itself a concern.

Benzodiazepines are controlled drugs in the UK, and flurazepam falls within the class of substances subject to misuse regulations . In Denmark, the regulatory approach to benzodiazepines is similarly restrictive.

The practical takeaway is straightforward. Dalmane 30 mg is a long-acting hypnotic with a metabolite that can persist for days. It is not a casual sleep aid, and it is not appropriate for older adults or anyone who needs to drive or operate machinery the following day. Short-term use—the FDA label and clinical references point to seven to ten days—is the only context in which it was ever considered reasonable . For most people with insomnia in the UK or Denmark today, safer and shorter-acting options exist, and a conversation with a prescriber is a better starting point than a long-half-life benzodiazepine from an unfamiliar source.